Affordable Access

deepdyve-link
Publisher Website

MS80, a novel sulfated oligosaccharide, inhibits pulmonary fibrosis by targeting TGF-beta1 both in vitro and in vivo.

Authors
  • Jiang, Han-Dong1
  • Guan, Hua-Shi
  • 1 School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China. , (China)
Type
Published Article
Journal
Acta Pharmacologica Sinica
Publisher
Springer Nature
Publication Date
Jul 01, 2009
Volume
30
Issue
7
Pages
973–979
Identifiers
DOI: 10.1038/aps.2009.86
PMID: 19543300
Source
Medline
License
Unknown

Abstract

MS80 in particular, and perhaps oligosaccharide in general, offer better pharmacological profiles with appreciably few side effects and represent a promising class of drug candidates for IPF therapy.Acta Pharmacologica Sinica (2009) 30: 973-979; doi: 10.1038/aps.2009.86; published online 22 June 2009.

Report this publication

Statistics

Seen <100 times